Impact of pharmacological correction on pathophysiological peculiarities of morpho-functional changes in lower urinary ways in experimental hyperactive bladder
Objective. Investigation of restorative processes in the lower urine-excreting ways under the influence of pharmacotherapy, and determination of the most perspective model of the experimental hyperactive bladder (HAB) treatment.
Маterials and methods. Еxperimental investigations were conducted on 120 sexually mature white male rats, in which a HAB was simulated. After creation of a hyperactive bladder (HAB) the laboratory animals were divided into four groups. Тhe laboratory animals of every one of three groups, except the fourth, were further divided into three subgroups, and in every subgroup pharmacocorrection was applied in various combinations.
Histological investigations of the bladder and urethra were conducted after exclusion of laboratory animals from the experiment in 14 and 28 days.
Results. The detrusor hyperactivity of the bladder have been lowered under the influence of pharmacotherapy, conducted in all the laboratory animals groups. In a group of laboratory animals, in which spasmex was applied, the signs of atony were less pronounced, that in group of laboratory animals, in which mirabegron was injected. Міrabegron in combination with other preparations have lowered the detrusor tone in laboratory animals of all three subgroups significantly. Less pronounced signs of the detrusor atony, than in laboratory animals, in which mirabegron served as a background preparation, were observed in laboratory animals, to which testosterone and estradiol were injected. The detrusor tone was restored almost to the physiological norm level in all subgroups of laboratory animals, to which quercetin was injected with other preparations.
Conclusion. Spasmolytic preparations reduce the detrusor tone, but cause the bladder overstretching. Combination of quercetin with і статевими hormones, restorating the organ physiological state, have affected the bladder detrusor hyperactivity most favorably.
2. Foditsch EE, Roider K, Patras I, Hutu I, Bauer S, Janetschek G, Zimmermann R. Structural changes of the urinary bladder afer chronic complete spinal cord injury in minipigs. Int Neurourol J. 2017;(21):12-9. http://doi.org/10.5213/inj.1732666.333.
3. Kubota Y, Kojima Y, Shibata Y, Imura M, Sasaki S, Kohri K. Role of KIT-positive interstitial cells of Cajal in the urinary bladder and possible therapeutic target for overactive bladder Adv Urol. 2011;(11):816342. http://doi.org/10.1155/2011/816342.
4. Ljubarskaja JuO, Atduev VA. Giperaktivnyj mochevoj puzyr’ Remedium Privolzh’e. 2014;(5):36-7 [In Russian].
5. Karpov EI. Lechenie giperaktivnogo mochenogo puzirja: rasshirjaem gorizonty. Medicinskij sovet. 2016;(10):140-2. http://doi.org/10.21518/2079-701X-2016-10-140-142. [In Russian].
6. Khullar V, Amarenco G, Angulo JC. Efficacy and tolerability of mirabegron, a 3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian Phase 3 Trial. Eur Urol. 2013Feb;63(2):283-95. http://doi.org/10.1016/j.eururo.2012.10.016.
7. Trubnikova NN, Fedorova AA, Revjakina EG. Vliianie urovnia polovyh gormonov na aktivnost antioksidantnoj sistemy. Patologіja. 2008;(2):66-7 [In Russian].
8. Berdicheskij VB. Giperaktivnyj mochevoj puzyr’. Medicinskaja nauka i obrazovanie Urala. 2015;(2) :146-9 [In Russian].
9. Avtandilov GG. Osnovy patologoanatomicheskoj praktiki. Rukovodstvo (izdanie trete dopolnennoe). Moskva: Rossijskaja medicinskaja akademija poslediplomnogo obrazovanija; 2007. 480 р. [In Russian].
10. Vishwajit S, Fuelhase C, Badlani GH. The biochemistry of wound healing in the pelvic floor: what have we learned? Current bladder dysfunction reports. 2009 March, 4(1): 13-19. http://doi.org/10.1007/s11884-009-0003-5.
This work is licensed under a Creative Commons Attribution 4.0 International License.